BORTEZOMIB
- Product NDC
- 10019-991
- 11-digit product format
- 100190991
- Labeler code
- 10019
- Product ID
- 10019-991_d8d0b49f-bf01-47f6-9e7a-40f203f95f28
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- bortezomib
- Dosage form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Route
- INTRAVENOUS; SUBCUTANEOUS
- Labeler
- Baxter Healthcare Corporation
- Application
- ANDA213823
- Marketing category
- ANDA
- Marketing start
- 2022-05-02
- Marketing end
- 0000-00-00
- Substance
- BORTEZOMIB
- Active strength
- 4 mg/1
- Pharmacologic classes
- Proteasome Inhibitor [EPC], Proteasome Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2023-12-31
- Current FDA listing
- Historical FDA.report record
DailyMed Dashboard NDC Coverage#
NDC, Dashboard title, SPL version table| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|
| 10019-991 | BORTEZOMIB INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [BAXTER HEALTHCARE CORPORATION] | 7 | Legacy NDC | 20250209_5ba41024-53f5-40a1-88c7-591d588599b7.zip |
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 10019-991-01 | 10019099101 | 1 VIAL, SINGLE-DOSE in 1 CARTON (10019-991-01) > 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE | 2022-05-02 | 0000-00-00 | No | No | Current |